Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effects of IFIH1 rs1990760 variants on systemic inflammation and outcome in critically ill COVID-19 patients in an observational translational study

  • Amado-Rodríguez, Laura|||0000-0002-8793-0213
  • Salgado del Riego, Estefania
  • Gomez de Ona, Juan
  • López Alonso, Inés
  • Gil-Pena, Helena
  • López-Martínez, Cecilia
  • Martín-Vicente, Paula
  • Lopez-Vazquez, Antonio
  • Gonzalez Lopez, Adrian
  • Cuesta-Llavona, Elias|||0000-0002-0924-0962
  • Rodriguez-Garcia, Raquel
  • Boga, Jose Antonio|||0000-0002-5500-9972
  • Elena alvarez-Arguelles, Marta
  • Mayordomo-Colunga, Juan|||0000-0003-0997-4410
  • Vidal-Castineira, Jose Ramon
  • Crespo, Irene
  • Fernandez, Margarita
  • Criado, Loreto
  • Salvadores, Victoria
  • Jimeno-Demuth, Francisco Jose
  • Blanch, Lluís|||0000-0002-4158-7464
  • Prieto, Belen
  • Fernandez-Fernandez, Alejandra
  • Lopez-Larrea, Carlos
  • Coto, Eliecer
  • Albaiceta, Guillermo M.|||0000-0002-9276-3253
Variants in IFIH1, a gene coding the cytoplasmatic RNA sensor MDA5, regulate the response to viral infections. We hypothesized that IFIH1 rs199076 variants would modulate host response and outcome after severe COVID-19. Patients admitted to an intensive care unit (ICU) with confirmed COVID-19 were prospectively studied and rs1990760 variants determined. Peripheral blood gene expression, cell populations, and immune mediators were measured. Peripheral blood mononuclear cells from healthy volunteers were exposed to an MDA5 agonist and dexamethasone ex-vivo, and changes in gene expression assessed. ICU discharge and hospital death were modeled using rs1990760 variants and dexamethasone as factors in this cohort and in-silico clinical trials. About 227 patients were studied. Patients with the IFIH1 rs1990760 TT variant showed a lower expression of inflammation-related pathways, an anti-inflammatory cell profile, and lower concentrations of pro-inflammatory mediators. Cells with TT variant exposed to an MDA5 agonist showed an increase in IL6 expression after dexamethasone treatment. All patients with the TT variant not treated with steroids survived their ICU stay (hazard ratio [HR]: 2.49, 95% confidence interval [CI]: 1.29-4.79). Patients with a TT variant treated with dexamethasone showed an increased hospital mortality (HR: 2.19, 95% CI: 1.01-4.87) and serum IL-6. In-silico clinical trials supported these findings. COVID-19 patients with the IFIH1 rs1990760 TT variant show an attenuated inflammatory response and better outcomes. Dexamethasone may reverse this anti-inflammatory phenotype. Centro de Investigación Biomédica en Red (CB17/06/00021), Instituto de Salud Carlos III (PI19/00184 and PI20/01360), and Fundació La Marató de TV3 (413/C/2021). Patients with severe COVID-19 often need mechanical ventilation to help them breathe and other types of intensive care. The outcome for many of these patients depends on how their immune system reacts to the infection. If the inflammatory response triggered by the immune system is too strong, this can cause further harm to the patient. One gene that plays an important role in inflammation is IFIH1 which encodes a protein that helps the body to recognize viruses. There are multiple versions of this gene which each produce a slightly different protein. It is possible that this variation impacts how the immune system responds to the virus that causes COVID-19. To investigate, Amado-Rodríguez, Salgado del Riego et al. analyzed the IFIH1 gene in 227 patients admitted to an intensive care unit in Spain for severe COVID-19 between March and December 2020. They found that patients with a specific version of the gene called TT experienced less inflammation and were more likely to survive the infection. Physicians typically treat patients with moderate to severe COVID-19 with corticosteroid drugs that reduce the inflammatory response. However, Amado-Rodríguez, Salgado del Riego et al. found that patients with the TT version of the IFIH1 gene were at greater risk of dying if they received corticosteroids. The team then applied the distribution of IFIH1 variants among different ethnic ancestries to data from a previous clinical trial, and simulated the effects of corticosteroid treatment. This 'mock' clinical trial supported their findings from the patient-derived data, which were also validated by laboratory experiments on immune cells from individuals with the TT gene. The work by Amado-Rodríguez, Salgado del Riego et al. suggests that while corticosteroids benefit some patients, they may cause harm to others. However, a real-world clinical trial is needed to determine whether patients with the TT version of the IFIH1 gene would do better without steroids.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Objective and subjective cognition in survivors of COVID-19 one year after ICU discharge, the role of demographic, clinical, and emotional factors

  • Godoy-González, Marta|||0000-0002-1374-918X
  • Navarra-Ventura, Guillem|||0000-0001-9839-7357
  • Gomà, Gemma|||0000-0002-1890-4855
  • Haro López, Candelaria de|||0000-0002-2668-1030
  • Espinal, Cristina|||0000-0001-8701-9983
  • Ridao, Natalia
  • Miguel Rebanal, Nuria
  • Oliveras-Furriols, Laia
  • Subirà, Carles|||0000-0003-2285-2311
  • Jódar Vicente, Mercè|||0000-0002-8913-5977
  • Santos-Pulpon, Verónica|||0000-0003-2685-9377
  • Sarlabous, Leonardo|||0000-0002-0495-8422
  • Fernández, Rafael
  • Ochagavía Calvo, Ana|||0000-0002-0564-2913
  • Blanch, Lluís|||0000-0002-4158-7464
  • Roca Gas, Oriol|||0000-0003-3841-4551
  • López-Aguilar, Josefina|||0000-0003-2359-3980
  • Fernández-Gonzalo, Sol|||0000-0003-0267-0617
Intensive Care Unit (ICU) COVID-19 survivors may present long-term cognitive and emotional difficulties after hospital discharge. This study aims to characterize the neuropsychological dysfunction of COVID-19 survivors 12 months after ICU discharge, and to study whether the use of a measure of perceived cognitive deficit allows the detection of objective cognitive impairment. We also explore the relationship between demographic, clinical and emotional factors, and both objective and subjective cognitive deficits. Critically ill COVID-19 survivors from two medical ICUs underwent cognitive and emotional assessment one year after discharge. The perception of cognitive deficit and emotional state was screened through self-rated questionnaires (Perceived Deficits Questionnaire, Hospital Anxiety and Depression Scale and Davidson Trauma Scale), and a comprehensive neuropsychological evaluation was carried out. Demographic and clinical data from ICU admission were collected retrospectively. Out of eighty participants included in the final analysis, 31.3% were women, 61.3% received mechanical ventilation and the median age of patients was 60.73 years. Objective cognitive impairment was observed in 30% of COVID-19 survivors. The worst performance was detected in executive functions, processing speed and recognition memory. Almost one in three patients manifested cognitive complaints, and 22.5%, 26.3% and 27.5% reported anxiety, depression and post-traumatic stress disorder (PTSD) symptoms, respectively. No significant differences were found in the perception of cognitive deficit between patients with and without objective cognitive impairment. Gender and PTSD symptomatology were significantly associated with perceived cognitive deficit, and cognitive reserve with objective cognitive impairment. One-third of COVID-19 survivors suffered objective cognitive impairment with a frontal-subcortical dysfunction 12 months after ICU discharge. Emotional disturbances and perceived cognitive deficits were common. Female gender and PTSD symptoms emerged as predictive factors for perceiving worse cognitive performance. Cognitive reserve emerged as a protective factor for objective cognitive functioning. Trial registration : ClinicalTrials.gov Identifier: NCT04422444; June 9, 2021. The online version contains supplementary material available at 10.1186/s13054-023-04478-7.